Navigation Links
WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals' CEO
Date:8/19/2007

NEW YORK, Aug. 8 /PRNewswire-FirstCall/ -- On August 7, J. J. Finkelstein, Chief Executive Officer of RegeneRx Biopharmaceuticals (Amex: RGN) updated the investment community in an all-new interview with http://www.wallst.net. Topics covered in the interview include RegeneRx Biopharmaceuticals' clinical trials, market potential, competitive edge, recent news, and milestones for which investors should watch.

To hear the interview in its entirety, visit http://www.wallst.net, and click on "Interviews." The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews" section of the site, or by entering the company's ticker symbol in the Search Archive window.

About RegeneRx Biopharmaceuticals:

RegeneRx, headquartered in Bethesda, Maryland, is a publicly-traded biopharmaceutical company focused on the discovery and development of novel molecules to accelerate tissue and organ repair. The Company is currently sponsoring five clinical trials for dermal wound healing, ophthalmic wound healing, and cardiovascular protection and regeneration after heart attack.

RegeneRx utilizes an outsourcing business model in order to effectively control costs while focusing on clinical development of its drug candidates. This model is used for research and development, manufacturing, drug formulation and clinical trials, as well as for other functions critical to its mission and enhances RegeneRx's ability to allocate resources rapidly to different projects without having to invest in infrastructure.

For more information about this Company, please visit http://www.regenerx.com.

About WallSt.net:

http://www.wallst.net is owned and operated by WallStreet Dire
'/>"/>

SOURCE Financial Filings Corp.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2

Related medicine technology :

1. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
2. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
3. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
4. NCCN Updates Esophageal and Gastric Cancer Guidelines
5. Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients
6. Tercica to Present at Investment Conferences
7. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
8. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
9. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
10. Trial Results with Intranasal Fentanyl Hold Promise for Treatment of Breakthrough Pain in Cancer
11. Hemispherx Presents Potential Avian Influenza Treatment Breakthrough at Paris Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... , PRINCETON, N.J., Nov. 20 /PRNewswire-Firs...X) (Soligenix or the Company), formerly known as D...pany, announced today that it has formed a consort...RiVax(TM) and other rapidly acting vaccines. Solig...al Institute of Allergy and Infectious Diseases (N...
(Date:11/19/2009)... , LYON, France, Nov. 19 In re...pplying dangerous and illegal medicines, Operation...d by INTERPOL and the World Health Organization,s ... Taskforce (IMPACT) to highlight the dangers of bu...initiative resulted in a series of arrests and the...
(Date:11/19/2009)... , MOUNTAIN VIEW, Calif., Nov. 19 /PRNewswire-...: ALXA ) announced today that its corporate prese...l Piper Jaffray Health Care Conference on Wednesda...e presentation will be webcast from The New York P...homas B. King, Alexza President and CEO. ,, T...
Breaking Medicine Technology:Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 3Childhood Brain Cancer Causes Other Long Term Problems 60506 1Childhood Brain Cancer Causes Other Long Term Problems 60506 2Asian Optical Retailers Upbeat about 2010 60503 1Asian Optical Retailers Upbeat about 2010 60503 2Asian Optical Retailers Upbeat about 2010 60503 3Helmets for Hope Campaign and Gala 60499 1Helmets for Hope Campaign and Gala 60499 2
..., 2007 - Pluristem Life Systems,Inc. (OTCBB:PLRS)...o the commercialization of products for a variety ...ions, announced today that,Pluristem,s PLacenta eX... to have properties that the Company believes give...isease (PD). PLX cells,are Pluristem,s placental-d...
... Improvement in Signs and,Symptoms Of Moderate to ...ents Achieving Disease Remission at One-Year,Mar...r data show nearly,75 percent of patients with mod...g golimumab (CNTO 148) and methotrexate (MTX),expe...ment in,arthritis symptoms (ACR 20). This was acco...
Other Medicine Technology:Pluristem's PLX Cells Demonstrate Potential to Treat Parkinson's,Disease 2Pluristem's PLX Cells Demonstrate Potential to Treat Parkinson's,Disease 3Pluristem's PLX Cells Demonstrate Potential to Treat Parkinson's,Disease 4Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid,Arthritis Study 2Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid,Arthritis Study 3Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid,Arthritis Study 4Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid,Arthritis Study 5
(Date:11/21/2009)...ides for an unprecedented expansion of federally-f... not for preserving and protecting human life? If ...armaine Yoest ,, WASHINGTON, Nov. 21 /PRNewsw...n President and CEO Dr. Charmaine Yoest responded ...ollowing statement: ,, "This was a pro-abortio...
(Date:11/21/2009)...sed medical credentialing software company Intelli...partnerhsip with Amerinet, Inc., the leading healt...lp to transform quality care within the healthcare...er 21, 2009 -- ISG Group, LLC, doing business as I...th Amerinet Inc., a leading national healthcare gr...
(Date:11/21/2009)...od Group ask whether there is a secret to ,alcohol... London, UK (PRWEB) November 21, 2... three of the adult UK population drinking enough ...ated liver disease*, it is hardly a surprise that ...ogrammes and residential centres for help. However...
(Date:11/20/2009)...20 Following a recall by Unilever ...om sale Shedd,s Country Crock ® Side Dishes D...ock ® Side Dishes DELUXE Four Cheese Pasta du...llowing code dates and UPCs are affected: ,, S...ddar Broccoli Rice 21 oz, UPC 027400218316, Best B...
(Date:11/20/2009)..., November 20 Cardio Vas...CVSLMEDICAL.COM , a leading,developer of advanced ... that,the company,s Board of Directors has decided... and the Far East for its proprietary next-generat...plasty (PCTA) procedures. , Cardio Vascul...
Breaking Medicine News(10 mins):Health News:Leading Anti-Abortion Group Vows to Vigorously Fight the Senate Health Bill 2Health News:IntelliSoft Group and Amerinet Inc. Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 4Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2
...th plan in Indiana experienced a 50 percent member... INDIANAPOLIS, May 30 MDwise employees today are,...old, not-for-profit,Indiana managed health care pl...yee base by 182 percent -- going from just,over 50...
...courages everyone to learn CPR/AED, WASHINGTON, M...ore than 166,000 people in this country every year...uffer sudden cardiac arrest,die before reaching a ...st waiting for help to arrive, many,thousands of l...
...- Mayo Clinic researchers have developed an animal... tumor suppressor genes, p16 and p19, in the aging...re expressed at increased levels as humans and mic... stops that process. , The findings, to be publis...
...30 Stronger health,systems, improved maternal and...d other infectious diseases are essential to Afric...today., These health priorities were highlighted ...organizations., Under the theme, "Towards a vibra...
...men tend to whet men,s sexual appetite. But stimul...arch says there,s more than meets the eye. A recen...handled lingerie sought immediate gratificationeve...ound that the desire for immediate rewards increas...
...quipment weight makes for temporary height loss, s...ws) -- Repetitive blocking and the weight of helme...t in a temporary loss of height for some football ...rcent of their height in a normal day. Fortunately...
Other Medicine News:Health News:MDwise Enrollment Exceeds 300,000 Members 2Health News:National CPR/AED Awareness Week 2Health News:Stronger Health Systems and Better Maternal Health Critical to African Development, Japan Summit Affirms 2Health News:Stronger Health Systems and Better Maternal Health Critical to African Development, Japan Summit Affirms 3Health News:Football Can Shrink Players 2
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
Medicine Products: